The medical loss ratio and its required spending on medical care creates a perverse incentive for people to spend more money on medical services, according to Margaret E. O’Kane, MHA. She added that while the rule came out of a motivation to restrict profits, the unintended consequence of the 80% to 85% rule is worrying.
Leah Binder agreed that the rule provides an incentive for plans to spend too much, but one thing she hopes ends up in the final rule is the transparency provision. “That really is requiring plans to be transparent about their network,” she said. “Who’s in the network, etc.”
However, the panelists all discussed how much consumers actually use the information being made available to them. O’Kane believes that the industry expects too much of consumers in terms of active shopping.
“I believe in transparency, I just don’t think we should get too complacent thinking if you just put the information out there, that solves the problems,” she said.
Austin Frakt pointed out that in the case of patients with substance use and mental health disorders, they are the highest cost patients, but they might not be in a position to use information made available to them. However, while Binder disagreed specifically about these patients, because often families of the patient make decisions in those instances, she agreed that traditionally consumers do not use quality information even when it’s available. But that is changing.
“In the private sector more people have high-deductible plans and they need to pay the whole bill out of their pocket, so they’re very interested in the price of care,” she said. “And that has brought them to the table to also look at quality, because price is not enough information. Once you know how much it is, you want to know how to get it.”
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More